BTK and B-cell chronic lymphocytic leukemia: For example, combination of venetoclax with BTK inhibitor ibrutinib or acalabrutinib with or without chemoimmunotherapy with obinutuzumab as frontline treatment for CLL has received positive outcomes in several phase II trials (NCT02910583, NCT03580928, and NCT02756897).429, 663, 664